Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02639299 · ClinicalTrials.gov registry record

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

A clinical trial of Malaria, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Recruiting
Registry status
1,500
Enrollment target
1
Study location

NCT02639299: Recruiting study of Malaria, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT02639299 is a study of Malaria that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,500 participants, above the 203-participant average among 27 other Malaria trials with a reported enrollment target (639% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02639299, a study of Malaria, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

RECRUITING
Registry status
1,500 participants
Enrollment target
1
Study location

Study Summary

Background: Malaria is a serious infection caused by a parasite. People get malaria when an infected mosquito bites them. Malaria can cause major health and social problems in places were malaria is common, such as Africa but can also affect travelers who have never been exposed to malaria. Researchers at the NIH want to find a safe and effective malaria vaccine, antimalarial drugs, or prevention regimen. To do this, healthy volunteers are recruited under a general screening study in order to see if are qualified to join a future malaria study. Objective: To screen healthy volunteers to see if they are eligible to join investigational malaria studies. The studies will be trials of investigational antimalarial drugs, malaria vaccines, or prevention regimens. They may also involve controlled human malaria infection trials. Eligibility: Healthy people ages 18 50 Design: Participants will first be prescreened by phone. Participants will be screened with: Medical history Physical exam Blood and urine tests Participants may go more than 1 year without joining a clinical trial. If this happens, they may be re-contacted to see if they still want to be part of this screening protocol. Those who still want to participate and have had relevant medical changes will be rescreened.

Primary Outcome

identify healthy adults at a low risk of developing complications due to experimental malaria infection, investigational antimalarials and vaccines

Conditions Studied

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2016-12-08
Est. Completion 2030-09-30

What NCT02639299 shows while recruiting

NCT02639299 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 203-participant average among 27 other Malaria trials with a reported enrollment target (639% higher).

The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 0 interventions.

NCT02639299 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02639299 about?

NCT02639299 is a clinical study titled "Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge". Background: Malaria is a serious infection caused by a parasite. People get malaria when an infected mosquito bites them. Malaria can cause major health and social problems in places were malaria is common, such as Africa but can also affect travelers who have never been exposed to malaria. Researc...

What is the current status of trial NCT02639299?

This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2016-12-08. Estimated completion is 2030-09-30.

What conditions does trial NCT02639299 study?

This clinical trial studies the following conditions: Malaria.

Who is sponsoring clinical trial NCT02639299?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02639299 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malaria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02639299's enrollment target sits among peer trials

1,500 2nd of 27 the highest of 27 other Malaria trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00178724 · 1,500 participants

    Spinal Cord Injury Registry - North American Clinical Trials Network

  • NCT00951366 · 1,500 participants

    Preterm Lung Patient Registry

  • NCT01050504 · 1,500 participants

    Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

  • NCT02071134 · 1,500 participants

    Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02639299, the US trial registry maintained by the National Library of Medicine. NCT02639299 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.